annb0t
Top 20
MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study that will bridge to Telix's global Phase III 'ZIRCON' trial of TLX250-CDx (89Zr-girentuximab), for the imaging of clear cell renal cell carcinoma (ccRCC) with position emission tomography (PET). (PRNewsfoto/Teli...
>>> Read more: Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
>>> Read more: Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
